Patents by Inventor Jivn-Ren Chen
Jivn-Ren Chen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7094426Abstract: The present invention relates to new stable enteric coated pharmaceutical dosage forms for oral use containing Omeprazole or Lansoprazole, to a formulation and a method for the manufacture of such a dosage forms, and to a method of gastric acid pump inhibition and providing gastrointestinal cytoprotective benefit by using them.Type: GrantFiled: April 26, 2004Date of Patent: August 22, 2006Assignee: Sage Pharmaceuticals, Inc.Inventor: Jivn-Ren Chen
-
Patent number: 7041316Abstract: The present invention relates to new stable enteric coated pharmaceutical dosage forms for oral use containing Omeprazole or Lansoprazole, to a formulation and a method for the manufacture of such a dosage forms, and to a method of gastric acid pump inhibition and providing gastrointestinal cytoprotective benefit by using them.Type: GrantFiled: April 24, 2003Date of Patent: May 9, 2006Assignee: Sage Pharmaceuticals, Inc.Inventor: Jivn-Ren Chen
-
Patent number: 6987133Abstract: This invention relates to a topical spray preparation for burn treatment and microbial infections on human being or animals. This non-aerosol preparation contains an antimicrobial drug, i.e., silver sulfadiazine, as is dispersed or solubilized in a cream or lotion base matrix which can be sprayed directly from a common trigger spray device. The key component of the matrix can be characterized by it having a suitable molecular weight polymer of cross-linked acrylic acid, such as Carbomers or non-ionic surfactants such as polyoxyethylene alkyl ethers, or any combination of the above materials.Type: GrantFiled: April 1, 2003Date of Patent: January 17, 2006Assignee: Sage Pharmaceuticals, Inc.Inventor: Jivn-Ren Chen
-
Publication number: 20040197394Abstract: The present invention relates to new stable enteric coated pharmaceutical dosage forms for oral use containing Omeprazole or Lansoprazole, to a formulation and a method for the manufacture of such a dosage forms, and to a method of gastric acid pump inhibition and providing gastrointestinal cytoprotective benefit by using them.Type: ApplicationFiled: April 26, 2004Publication date: October 7, 2004Applicant: Sage Pharmaceuticals, Inc.Inventor: Jivn-Ren Chen
-
Patent number: 6726927Abstract: The present invention relates to new stable enteric coated pharmaceutical dosage forms for oral use containing Omeprazole or Lansoprazole, to a formulation and a method for the manufacture of such a dosage forms, and to a method of gastric acid pump inhibition and providing gastrointestinal cytoprotective benefit by using them.Type: GrantFiled: August 27, 1998Date of Patent: April 27, 2004Assignee: Sage Pharmaceuticals, Inc.Inventor: Jivn-Ren Chen
-
Patent number: 6645508Abstract: A stable composition including a water-sensitive pharmacologically active agent, such as an enzyme, an antibiotic or a vitamin, a hydrophilic non-polar primary solvent, an optional hydrophilic non-polar secondary solvent and optional pharmaceutical or cosmetic adjuvants to enhance appearance for topical use. Where the water-sensitive or water-degradable component is L-Ascorbic acid and the principal solvent is N-methyl-2-pyrrolidone (“NMP”) the composition is stable for many months at a concentration of L-Ascorbic acid of up to about 40 % w/v. This composition using NMP as a solvent and enhancer of skin penetration together with appropriate adjuvants is useful for preparing dermatological topical dosage for cosmetic and therapeutic purposes.Type: GrantFiled: June 18, 1999Date of Patent: November 11, 2003Inventor: Jivn-Ren Chen
-
Publication number: 20030203018Abstract: The present invention relates to new stable enteric coated pharmaceutical dosage forms for oral use containing Omeprazole or Lansoprazole, to a formulation and a method for the manufacture of such a dosage forms, and to a method of gastric acid pump inhibition and providing gastrointestinal cytoprotective benefit by using them.Type: ApplicationFiled: April 24, 2003Publication date: October 30, 2003Applicant: Sage Pharmaceuticals, Inc.Inventor: Jivn-Ren Chen
-
Publication number: 20030170182Abstract: This invention relates to a topical spray preparation for burn treatment and microbial infections on human being or animals. This non-aerosol preparation contains an antimicrobial drug, i.e., silver sulfadiazine, as is dispersed or solubilized in a cream or lotion base matrix which can be sprayed directly from a common trigger spray device. The key component of the matrix can be characterized by it having a suitable molecular weight polymer of cross-linked acrylic acid, such as Carbomers or non-ionic surfactants such as polyoxyethylene alkyl ethers, or any combination of the above materials.Type: ApplicationFiled: April 1, 2003Publication date: September 11, 2003Applicant: Sage Pharmaceuticals, Inc.Inventor: Jivn-Ren Chen
-
Patent number: 6551577Abstract: This invention relates to a topical spray preparation for burn treatment and microbial infections on human being or animals. This non-aerosol preparation contains an antimicrobial drug, i.e., silver sulfadiazine, as is dispersed or solubilized in a cream or lotion base matrix which can be sprayed directly from a common trigger spray device. The key component of the matrix can be characterized by it having a suitable molecular weight polymer of cross-linked acrylic acid, such as Carbomers or non-ionic surfactants such as polyoxyethylene alkyl ethers, or any combination of the above materials.Type: GrantFiled: June 23, 1999Date of Patent: April 22, 2003Assignee: Sage Pharmaceuticals, Inc.Inventor: Jivn-Ren Chen
-
Publication number: 20010006649Abstract: The present invention relates to new stable enteric coated pharmaceutical dosage forms for oral use containing Omeprazole or Lansoprazole, to a formulation and a method for the manufacture of such a dosage forms, and to a method of gastric acid pump inhibition and providing gastrointestinal cytoprotective benefit by using them.Type: ApplicationFiled: August 27, 1998Publication date: July 5, 2001Inventor: JIVN-REN CHEN
-
Patent number: 5225204Abstract: A stable dosage form of levothyroxine sodium which includes a stable complex of levothyroxine sodium and a cellulose compound, polyvinylpyrrolidone or a Poloxamer, which complex is adsorbed on the surface of a cellulose compound carrier. In a first embodiment the stable complex of levothyroxine sodium is prepared by mixing the levothyroxine sodium with a complexing agent such as polyvinylpyrrolidone or a Poloxamer, dissolving the resulting mixture in a polar organic solvent such as water, methanol, ethanol, propanol, isopropyl alcohol, methylene dichloride or butanol, adding a cellulose carrier to the liquid and subsequently drying the resulting mixture to obtain a powdery, stabilized complex of levothyroxine sodium and polyvinylpyrrolidone or Poloxamer adsorbed on the cellulose carrier. In a second embodiment the levothyroxine sodium is at least partially dissolved directly in the polar organic solvent and a cellulose carrier is added to the solution to produce the stabilized levothyroxine sodium complex.Type: GrantFiled: November 5, 1991Date of Patent: July 6, 1993Inventors: Jivn-Ren Chen, Dimitri C. Papadimitriou
-
Patent number: 5191114Abstract: Direct compressible ibuprofen particles are formed by treating commercially available, dry ibuprofen with a hydrophilic solvent in one embodiment, a mixture of a hydrophilic solvent and one or more hydrophobic organic solvents in a second embodiment and one or more hydrophobic organic solvents in a third embodiment, to change at least the external crystalline shape of the ibuprofen from a flow-retarding shape to a free-flowing, easily compressible configuration. A typical hydrophilic solvent is water and among the hydrophobic solvents which may be used are acetone, methyl alcohol, ethyl alcohol, isopropyl and N-propyl alcohol. Direct compressible ibuprofen particles having superior flow characteristics may also be prepared by mixing commercially available, dry ibuprofen with micron size, amorphous silica gel in various formulations.Type: GrantFiled: October 9, 1991Date of Patent: March 2, 1993Assignee: Sage Pharmaceuticals, Inc.Inventor: Jivn-Ren Chen
-
Patent number: 4575509Abstract: This invention concerns novel water-soluble salts and compositions of the antitumor agent 4'-(9-acridinylamino) methanesulfon-m-anisidide (m-AMSA). More particularly, there are provided (1) the mono- and dipyroglutamate salts of m-AMSA and (2) compositions of m-AMSA with pyroglutamic acid. The novel salts and compositions provided enable m-AMSA to be administered as an aqueous solution without the necessity of using dimethylacetamide as a pharmaceutical vehicle.Type: GrantFiled: July 18, 1984Date of Patent: March 11, 1986Assignee: Bristol-Myers CompanyInventors: Jivn-Ren Chen, Edward C. Shinal